A network meta-analysis comparing anti–PD-1 treatments in first-line GC/GEJC

In the absence of direct head-to-head RCTs, a network meta-analysis was performed to compare tislelizumab (TIS) plus chemotherapy (CT) with nivolumab (NIV) + CT and pembrolizumab (PEM) + CT in metastatic HER2-negative GC/GEJC. TIS+CT showed comparable efficacy across outcomes, with consistent results across PD-L1 subgroups. Safety analysis indicated significantly fewer grade ≥3 adverse events with TIS+CT compared to NIV+CT, and a similar safety profile to PEM+CT. These findings suggest a potential therapeutic advantage for TIS+CT due to its comparable efficacy and favourable safety. However, as NMAs rely on assumptions of trial similarity, results should be interpreted cautiously in the absence of head-to-head data.